Overview

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the pharmacokinetics (PK) in adult Chinese subjects with dry eye disease (DED)1 after bilateral nasal spray administration of OC-01 (varenicline solution) Nasal Spray at a concentration of 0.6 mg/mL.

Phase:

Phase 1

Details

Lead Sponsor:

Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Collaborator:

Oyster Point Pharma, Inc.

Treatments:

Varenicline